
OSTX Stock Forecast & Price Target
OSTX Analyst Ratings
Bulls say
OS Therapies is focusing on developing treatments for osteosarcoma and other solid tumors, with a potential market potential of $300M in Europe and $50M in 2027 sales. The company is expected to have key milestones, such as pre-BLA engagement with the FDA and regulatory meetings in Q2 2026, and potential accelerated approval decisions and PRV monetization in the second half of 2026. However, there are risks involved in the company's clinical and regulatory processes, as well as potential challenges in financing and maintaining market share.
Bears say
OS Therapies is a clinical-stage biopharmaceutical company that is developing a lead drug, OST-HER2, for the prevention or delay of recurrence in patients with fully resected pulmonary metastatic osteosarcoma. Despite promising potential, the company's pipeline is still in the preclinical stage and there is no current revenue. The recent initiation of a rolling review by the EMA is a positive validation, but more development and regulatory hurdles may still lie ahead before the company can generate any meaningful revenue.
This aggregate rating is based on analysts' research of OS Therapies Inc and is not a guaranteed prediction by Public.com or investment advice.
OSTX Analyst Forecast & Price Prediction
Start investing in OSTX
Order type
Buy in
Order amount
Est. shares
0 shares